The Institute for International Research (IIR) will be holding its 15th Annual Business of Biosimilars conference from October 20-22, 2014 in Boston, MA. The conference will offer presentations on the following topics:
Pre-Conference Day -- October 20:
• Around the World in 1 Day: Emerging Markets Pre-Conference Summit
• Women Leaders in Pharma Dinner
Main Conference Day One -- October 21:
• The Continuing Shakedown of Biosimilar Developers
• Looking at the Commercial Realities of the Biosimilar Market (panel)
• Business Opportunities in the US Market
• Understanding the Global Payer & Reimbursement Landscape
• Global Harmonization of Biosimilar Regulatory Pathways
• Takeaways on High Profile Court Cases (panel)
• Legal and IP Landscape for 2014 and Beyond
• News from the EU over the past 12 Months: Any Changes in European Biosimilar Guidelines, Approvals, and Perceptions?
• From the First European Biosimilar Epoetin Alfa Product to Third Wave Biosimilars — Experience Gained From Establishing Successful Development Organizations for Global Quality Biosimilars (case study)
• Partnership Spotlight: Penetrating Emerging Markets Hand in Hand (case study)
Main Conference Day Two -- October 22:
• Expert Opinions: Biosimilar Policies & Adoption (panel)
• Hit the Nail on the Head: Creating an Optimal Development Plan (case study)
• Alternatives to the "Abbreviated" Biosimilar Pathway: Full Applications in Biobetters
• "How to Play": Commercialization Strategy to Maximize Uptake and Market Potential
The agenda for the conference can be found here. A complete brochure for this conference, including an agenda, list of speakers, descriptions of the scheduled presentations, and registration information can be downloaded here.
The registration fee for this conference is $2,295 (conference only) or $2,895 (conference and workshop). Those registering before September 12, 2014 will receive a $200 discount. Those interested in registering for the conference can do so here.
Patent Docs is a media partner of the Business of Biosimilars conference.
Comments